Results 21 to 30 of about 686 (119)

Alveolar and interstitial disease in chronic smoker presenting as combined pulmonary fibrosis with emphysema: Double trouble!

Annals of Medical Science and Research, 2023
Tobacco smoke exposure causes diverse pulmonary manifestations with involvement of alveolar, interstitial, and vascular diseases due to inflammatory pathology apart from more lethal lung cancer. Combined pulmonary fibrosis and emphysema is a heterogenous
Shital Patil, Gajanan Gondhali
doaj   +1 more source

Combined pulmonary fibrosis with emphysema in nonsmokers needs connective tissue disease workup: A case report

The Journal of Association of Chest Physicians, 2023
Combined pulmonary fibrosis and emphysema (CPFE) is a heterogenous lung disease documented in smokers, which includes emphysema in upper lobes and pulmonary fibrosis in lower lobes. CPFE in nonsmokers is rare, and very few literatures are available.
Shital Patil, Sham Toshniwal
doaj   +1 more source

MRI of the lung (3/3)-current applications and future perspectives [PDF]

, 2011
BackgroundMRI of the lung is recommended in a number of clinical indications. Having a non-radiation alternative is particularly attractive in children and young subjects, or pregnant women.MethodsProvided there is sufficient expertise, magnetic ...
M. Both, Molinari, F., Mirsadraee, S., E. J. R. Van Beek, Molinari, F, Both, M, Beer, M., Bauman, G, Wild, J., Mirsadraee, S, Biederer, J, Hintze, C, Jürgen Biederer, J. Wild, S. Mirsadraee, Puderbach, M, Biederer, Jürgen, Wild, J, Bauman, G., M. Beer, M. Puderbach, Van Beek, E J R, Beer, M, Hintze, C., Both, M., G. Bauman, C. Hintze, Van Beek, EJR, F. Molinari, Van Beek, E. J. R., Puderbach, M.   +30 more
core   +2 more sources

Pulmonary hypertension associated with chronic lung diseases

Swiss Medical Weekly, 2016
In 2015, the international guidelines for diagnosis and treatment of pulmonary hypertension were updated. Group 3 of the current classification includes pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), interstitial ...
Manuela Funke, Thomas Geiser, Otto D. Schoch   +2 more
doaj   +1 more source

An increased risk of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema: a meta-analysis

BMC Pulmonary Medicine, 2023
Background and aim Pulmonary hypertension (PH) is a common complication of combined pulmonary fibrosis and emphysema (CPFE). Whether the incidence of PH is increased in CPFE compared with pure pulmonary fibrosis or emphysema remains unclear.
Hangqi Ni, Yuying Wei, Liuqing Yang, Qing Wang   +3 more
doaj   +1 more source

Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement [PDF]

, 2022
Background: The presence of emphysema is relatively common in patients with fibrotic interstitial lung disease. This has been designated combined pulmonary fibrosis and emphysema (CPFE).
Flaherty, Kevin R, Rebecca L. Morgan, Yoshikazu Inoue, Claudia Valenzuela, Inoue, Yoshikazu, Tonia, Thomy, Tae Iwasawa, Katerina M. Antoniou, Vincent Cottin, Occhipinti, Mariaelena, Fabian Caro, Wells, Athol U, Kitaichi, Masanori, Sin, Don D, Bianchi, Pauline, Iwasawa, Tae, Agusti, Alvar, Masanori Kitaichi, Myers, Jeffrey L, Florenzano, Matias, Martinez, Fernando J, Pauline Bianchi, Moises Selman, Fernando J. Martinez, Tamera J. Corte, Corte, Tamera J, MeiLan K. Han, Venerino Poletti, Selman, Moises, Jeffrey L. Myers, Lee, Joyce S, Sverzellati, Nicola, Alvar Agusti, Margaret L. Salisbury, Alyson W. Wong, Caro, Fabian, Don D. Sin, Valenzuela, Claudia, Han, MeiLan K, Nicholson, Andrew G, Kerri A. Johannson, Kevin R. Flaherty, Christopher J. Ryerson, Joyce S. Lee, Jacob, Joseph, Galvin, Liam, Thomy Tonia, Johannson, Kerri A, Morgan, Rebecca L, Antoniou, Katerina M, Mariaelena Occhipinti, Cottin, Vincent, Nicola Sverzellati, Wong, Alyson W, Joseph Jacob, Athol U. Wells, Liam Galvin, Salisbury, Margaret L, Poletti, Venerino, Andrew G. Nicholson, Ryerson, Christopher J, Matias Florenzano   +61 more
core   +2 more sources

Pirfenidone combined with N-acetylcysteine in treatment of pulmonary fibrosis: a case report and literature review [PDF]

Xin yixue, 2022
Objective To evaluate the efficacy and safety of pirfenidone combined with N-acetylcysteine （NAC） in the treatment of pulmonary fibrosis, aiming to provide basis for clinical medication. Methods Clinical data of 1 patient with combined pulmonary fibrosis
Li Wenjuan, Zhang Liyi, Zhou Yuqi
doaj   +1 more source

IgG4-related disease presenting with combined pulmonary fibrosis and emphysema (CPFE)

Respiratory Medicine Case Reports, 2018
A 64-year-old man was admitted to our hospital with an abnormal chest shadow. The patient was a current-smoker and had a past illness of autoimmune pancreatitis with a high serum level of IgG4, 348 mg/dL.
Masato Kono, Yutaro Nakamura, Yoshiyuki Oyama, Go Saito, Yu Koyanagi, Koichi Miyashita, Akari Tsutsumi, Yasunori Enomoto, Takeshi Kobayashi, Yoshihiro Miki, Dai Hashimoto, Noriyuki Enomoto, Thomas V. Colby, Takafumi Suda, Hidenori Nakamura   +14 more
doaj   +1 more source

Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort

, 2021
Rahul Sangani,1 Andrew Ghio,2 Stacey Culp,3 Zalak Patel,4 Sunil Sharma1 1Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, West Virginia University, Morgantown, WV, USA; 2Human Studies Facility, US Environmental Protection ...
Culp S, Sharma S, Sangani R, Ghio A, Patel Z   +4 more
core  

Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population

Kaohsiung Journal of Medical Sciences, 2017
In this study, we aimed to explore the association of genetic polymorphism in matrix metalloproteinase-9 (MMP-9) and transforming growth factor-β1 (TGF-β1) and the susceptibility to combined pulmonary fibrosis and emphysema (CPFE).
Ling Xu, Wei Bian, Xiao-Hua Gu, Ce Shen
doaj   +1 more source